Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • CGM
Posted inDiabetes & Endocrinology news

Why Time Below Range Is a Poor Standalone Predictor of Severe Hypoglycemia: Evidence from Six Clinical Trials

Posted by MedXY By MedXY 03/17/2026
A multi-trial analysis reveals that CGM-derived Time Below Range (TBR) lacks the predictive power to serve as a standalone biomarker for severe hypoglycemia, highlighting the need for multi-factorial risk assessment in Type 1 Diabetes.
Read More
What’s New in Diabetes Care 2024: Key Recommendations from the ADA Standards of Care
Posted inDiabetes & Endocrinology Specialties

What’s New in Diabetes Care 2024: Key Recommendations from the ADA Standards of Care

Posted by MedXY By MedXY 08/22/2025
A practical, clinician-friendly summary of the American Diabetes Association’s 2024 Standards of Care, highlighting new recommendations on GLP-1/GIP therapy, SGLT2 inhibitors, continuous glucose monitoring, and individualized care.
Read More
  • Robotic vs Laparoscopic Cholecystectomy: No Outcome Advantage Across Disease Severity Grades
  • Molecular Complexity of Endometrial Cancer: How Biomarker Patterns Vary Across Tumor Stages, Histology, and Molecular Subtypes
  • Evidence Gaps in Maternity Guidelines: RCOG Green-Top Guidelines Show Limited Health Equity Considerations in High-Quality Recommendations
  • Flash Glucose Monitoring Fails to Improve Glycemic Control but Reduces Large-for-Gestational-Age Risk in Gestational Diabetes
  • Beyond Simple Quantification: How AI and Tumor-Stroma Ratio Are Redefining Prognosis Prediction in Hepatocellular Carcinoma
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in